Mutual of America Capital Management LLC Sells 2,662 Shares of Zoetis Inc. (NYSE:ZTS)

Mutual of America Capital Management LLC reduced its holdings in Zoetis Inc. (NYSE:ZTS) by 4.4% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 57,671 shares of the company’s stock after selling 2,662 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Zoetis were worth $9,998,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in ZTS. Aveo Capital Partners LLC purchased a new position in shares of Zoetis in the 4th quarter worth about $225,000. Gryphon Financial Partners LLC boosted its holdings in Zoetis by 11.8% during the 4th quarter. Gryphon Financial Partners LLC now owns 3,056 shares of the company’s stock valued at $601,000 after acquiring an additional 322 shares during the period. Jump Financial LLC purchased a new stake in Zoetis during the 4th quarter valued at about $339,000. Level Four Advisory Services LLC boosted its holdings in Zoetis by 11.7% during the 4th quarter. Level Four Advisory Services LLC now owns 1,504 shares of the company’s stock valued at $297,000 after acquiring an additional 157 shares during the period. Finally, TrinityPoint Wealth LLC boosted its holdings in Zoetis by 0.3% during the 4th quarter. TrinityPoint Wealth LLC now owns 22,319 shares of the company’s stock valued at $4,405,000 after acquiring an additional 73 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Up 0.4 %

ZTS stock opened at $196.48 on Thursday. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The firm has a market cap of $89.65 billion, a PE ratio of 37.86, a price-to-earnings-growth ratio of 2.98 and a beta of 0.88. The business has a 50 day moving average of $184.11 and a 200 day moving average of $174.31.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. During the same period last year, the business posted $1.41 EPS. The company’s revenue was up 8.3% compared to the same quarter last year. On average, research analysts forecast that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Stifel Nicolaus increased their target price on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday. BTIG Research increased their price objective on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Piper Sandler increased their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Finally, Argus raised Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Zoetis currently has a consensus rating of “Buy” and a consensus target price of $218.22.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.